Celldex Therapeutics Inc (CLDX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLDX SEC filings page.
Celldex Therapeutics Inc (CLDX) reported $1.5M in revenue for fiscal year 2025, down 78.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Celldex’s dominant mechanic is development-stage reinvestment: escalating R&D spending drives cash consumption while financing, not revenue, funds the balance sheet.
Cash conversion is closely tracking reported losses: in FY2025, operating cash flow was-$210.9M against net income of-$258.8M , so non-cash items do not materially soften the economic cost of development. At the same time, revenue fell to$1.5M while R&D reached$245.1M , making the business’s financial profile increasingly determined by research investment rather than commercial activity.
R&D intensity accelerated across the latest two years, rising from
The balance sheet remains lightly debt-funded: debt-to-equity was only 0.1x and the current ratio was 10.5x in FY2025, while total liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Celldex Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Celldex Therapeutics Inc held $518.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $210.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Celldex Therapeutics Inc scores 54/100 among other emerging companies.
Celldex Therapeutics Inc had 67M shares outstanding at the end of fiscal year 2025, against 66M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Celldex Therapeutics Inc scores 49/100 among other emerging companies.
Celldex Therapeutics Inc spent $245.1M on research and development in fiscal year 2025, which was 84.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Celldex Therapeutics Inc scores 100/100 among other emerging companies.
Celldex Therapeutics Inc reported revenue of $1.5M in fiscal year 2025, against $7.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Celldex Therapeutics Inc scores 5/100 among other emerging companies.
Celldex Therapeutics Inc's operations used $210.9M of cash in fiscal year 2025, against $157.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Celldex Therapeutics Inc scores 19/100 among other emerging companies.
Celldex Therapeutics Inc's cash, cash equivalents and investments came to $518.6M at the end of fiscal year 2025, against $55.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Celldex Therapeutics Inc scores 96/100 among other emerging companies.
Celldex Therapeutics Inc scores 28.51, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.1B) relative to total liabilities ($55.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Celldex Therapeutics Inc passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Celldex Therapeutics Inc reported a net loss of $258.8M while operations used $210.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Celldex Therapeutics Inc generated $22K in revenue in Q2 2026. This represents a decrease of 97.0% from the same quarter a year earlier. Against the prior quarter it is up 46.7%.
Celldex Therapeutics Inc's EBITDA was -$79.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.6% from the same quarter a year earlier. Against the prior quarter it is up 4.6%.
Celldex Therapeutics Inc reported -$73.5M in net income in Q2 2026. This represents a decrease of 29.9% from the same quarter a year earlier. Against the prior quarter it is up 6.6%.
Celldex Therapeutics Inc earned -$0.94 per diluted share (EPS) in Q2 2026. This represents a decrease of 10.6% from the same quarter a year earlier. Against the prior quarter it is up 20.3%.
Cash & Balance Sheet
Celldex Therapeutics Inc recorded an outflow of $60.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 35.4% from the same quarter a year earlier. Against the prior quarter it is up 9.9%.
Celldex Therapeutics Inc held $47.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Celldex Therapeutics Inc's ROE was -10.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.0 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Celldex Therapeutics Inc invested $67.5M in research and development in Q2 2026. This represents an increase of 24.6% from the same quarter a year earlier. Against the prior quarter it is down 7.5%.
Celldex Therapeutics Inc invested $3.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 336.7% from the same quarter a year earlier. Against the prior quarter it is up 94.0%.
Not reported for Q2 2026.
CLDX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22K-97.0% | $15K-97.8% | N/A | N/A | $730K-70.8% | $695K+345.5% | $1.2M-71.6% | $3.2M+110.3% |
| R&D Expenses | $67.5M+24.6% | $73.0M+38.7% | N/A | $62.9M+39.0% | $54.2M+36.6% | $52.6M+66.2% | $46.9M+54.3% | $45.3M+31.1% |
| SG&A Expenses | $13.1M+26.1% | $11.4M+5.8% | N/A | $10.7M+6.3% | $10.4M+13.8% | $10.8M+18.9% | $10.3M+16.2% | $10.1M+22.3% |
| Operating Income | -$80.6M-26.3% | -$84.4M-34.6% | N/A | -$73.6M-41.2% | -$63.9M-37.9% | -$62.7M-54.5% | -$56.0M-17.6% | -$52.1M-26.4% |
| EBITDA | -$79.7M-26.6% | -$83.6M-35.1% | N/A | -$72.8M-41.8% | -$63.0M-38.4% | -$61.9M-55.3% | -$55.2M-17.8% | -$51.3M-26.9% |
| Net Income | -$73.5M-29.9% | -$78.7M-46.3% | N/A | -$67.0M-59.2% | -$56.6M-57.9% | -$53.8M-64.0% | -$47.1M-8.7% | -$42.1M-10.1% |
| EPS (Basic) | -$0.94-10.6% | -$1.18-45.7% | -$1.23-73.2% | -$1.01-57.8% | -$0.85-57.4% | -$0.81-44.6% | -$0.71+15.5% | -$0.64+21.0% |
| EPS (Diluted) | -$0.94-10.6% | -$1.18-45.7% | -$1.23-73.2% | -$1.01-57.8% | -$0.85-57.4% | -$0.81-44.6% | -$0.71+15.5% | -$0.64+21.0% |
| Diluted Shares (Avg) | 78M+17.2% | 67M+0.3% | N/A | 66,420+0.2% | 66M+100465.0% | 66M+112660.1% | N/A | 66,294+40.3% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
CLDX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $782.3M+13.0% | $511.3M-30.9% | $583.0M-26.4% | $648.4M-21.2% | $692.4M-18.1% | $739.5M-14.9% | $792.3M+70.2% | $823.2M+193.7% |
| Current Assets | $724.9M+11.8% | $459.2M-33.8% | $534.7M-28.4% | $604.3M-22.4% | $648.4M-20.1% | $693.8M-16.9% | $747.2M+73.1% | $778.8M+216.7% |
| Cash & Equivalents | $47.5M+105.9% | $35.7M+108.5% | $28.9M+1.8% | $36.0M-1.0% | $23.0M-46.1% | $17.1M-85.1% | $28.4M-18.6% | $36.4M+72.2% |
| Short-Term Investments | $670.1M+10.3% | $415.7M-36.6% | $489.7M-29.7% | $547.2M-24.0% | $607.3M-20.0% | $656.2M-7.4% | $696.9M+79.3% | $719.6M+235.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $67.8M+83.2% | $55.0M+50.8% | $55.8M+23.1% | $50.1M+34.3% | $37.0M+15.9% | $36.5M+20.7% | $45.3M+24.4% | $37.3M+11.1% |
| Current Liabilities | $61.3M+86.0% | $51.5M+60.8% | $51.0M+29.1% | $46.5M+44.8% | $33.0M+19.2% | $32.0M+21.8% | $39.5M+26.9% | $32.1M+15.3% |
| Non-Current Liabilities | $6.5M+60.0% | $3.6M-20.5% | $4.8M-17.3% | $3.6M-30.3% | $4.0M-5.4% | $4.5M+13.4% | $5.8M+9.4% | $5.2M-9.1% |
| Total Equity | $714.6M+9.0% | $456.2M-35.1% | $527.2M-29.4% | $598.4M-23.9% | $655.4M-19.4% | $703.0M-16.2% | $747.0M+74.1% | $785.9M+218.5% |
| Retained Earnings | -$2.0B-18.0% | -$1.9B-17.6% | -$1.8B-16.6% | -$1.7B-14.9% | -$1.7B-13.6% | -$1.6B-12.5% | -$1.6B-11.3% | -$1.5B-11.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CLDX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$57.4M-30.5% | -$65.6M-20.6% | -$63.9M-96.9% | -$48.6M+12.1% | -$44.0M-50.0% | -$54.4M-33.8% | -$32.5M+0.2% | -$55.3M-191.4% |
| Depreciation & Amortization | $902K+3.3% | $854K-1.5% | $816K-0.4% | $824K+4.8% | $873K+9.5% | $867K+11.9% | $819K+7.9% | $786K+2.5% |
| Stock-Based Compensation | $8.4M-8.5% | $8.5M-8.5% | N/A | $8.8M-8.5% | $9.2M+20.3% | $9.3M+29.4% | N/A | $9.6M+35.1% |
| Capital Expenditures | $3.2M+336.7% | $1.6M+518.5% | $1.3M+69.4% | $440K-19.3% | $728K+165.7% | $265K-23.0% | $756K+13.5% | $545K+247.1% |
| Free Cash Flow | -$60.6M-35.4% | -$67.2M-23.0% | -$65.2M-96.3% | -$49.1M+12.2% | -$44.7M-51.1% | -$54.6M-33.3% | -$33.2M-0.1% | -$55.9M-191.8% |
| Investing Cash Flow | -$255.5M-612.6% | $72.1M+67.9% | $55.4M+130.5% | $60.8M+27.4% | $49.9M+206.7% | $43.0M+113.6% | $24.0M+114.0% | $47.8M+310.1% |
| Financing Cash Flow | $324.7M+515228.6% | $327K+61.9% | $1.3M+249.5% | $774K-37.5% | $63K-98.3% | $202K-100.0% | $386K-99.8% | $1.2M+382.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CLDX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -366468.2% | -562900.0% | N/A | N/A | -8747.5% | -9027.2% | -4768.3% | -1633.5% |
| Net Margin | -334104.6% | -524566.7% | N/A | N/A | -7753.4% | -7740.4% | -4007.8% | -1320.0% |
| Return on Equity | -10.3%-1.7pp | -17.3%-9.6pp | N/A | -11.2%-5.8pp | -8.6%-4.2pp | -7.6%-3.7pp | -6.3%+3.8pp | -5.4%+10.1pp |
| Return on Assets | -9.4%-1.2pp | -15.4%-8.1pp | N/A | -10.3%-5.2pp | -8.2%-3.9pp | -7.3%-3.5pp | -5.9%+3.4pp | -5.1%+8.5pp |
| Current Ratio | 11.82-7.8x | 8.92-12.7x | 10.49-8.4x | 13.01-11.3x | 19.67-9.7x | 21.67-10.1x | 18.91+5.0x | 24.27+15.4x |
| Debt-to-Equity | 0.090.0x | 0.12+0.1x | 0.110.0x | 0.080.0x | 0.060.0x | 0.050.0x | 0.060.0x | 0.05-0.1x |
| Asset Turnover | 0.000.0x | 0.000.0x | N/A | N/A | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
| FCF Margin | -275404.6% | -448180.0% | N/A | N/A | -6127.8% | -7861.4% | -2828.3% | -1751.2% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Celldex Therapeutics Inc CLDX | FY2025 | $1.5M | -$258.8M | N/A | $3.1B | 54/100 |
| Cogent Biosciences Inc COGT | FY2025 | N/A | -$328.9M | N/A | $6.0B | — |
| Aurinia Pharmace AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.1B | 56/100 |
| Cidara Theraptcs CDTX | FY2024 | $1.3M | -$169.8M | N/A | $7.0B | 49/100 |
| Vera Therapeutics, Inc. VERA | FY2025 | N/A | -$299.6M | N/A | $2.6B | — |
| Ardelyx ARDX | FY2025 | $407.3M | -$62.0M | -15.2% | $975.9M | 45/100 |
Where Celldex Therapeutics Inc Ranks
Frequently Asked Questions
What is Celldex Therapeutics Inc's annual revenue?
Celldex Therapeutics Inc (CLDX) reported $1.5M in total revenue for fiscal year 2025. This represents a -78.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Celldex Therapeutics Inc's revenue growing?
Celldex Therapeutics Inc (CLDX) revenue declined by 78.0% year-over-year, from $7.0M to $1.5M in fiscal year 2025.
Is Celldex Therapeutics Inc profitable?
No, Celldex Therapeutics Inc (CLDX) reported a net income of -$258.8M in fiscal year 2025.
What is Celldex Therapeutics Inc's EBITDA?
Celldex Therapeutics Inc (CLDX) had EBITDA of -$284.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Celldex Therapeutics Inc's gross margin?
Celldex Therapeutics Inc (CLDX) had a gross margin of 87.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Celldex Therapeutics Inc's return on equity (ROE)?
Celldex Therapeutics Inc (CLDX) has a return on equity of -49.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Celldex Therapeutics Inc's free cash flow?
Celldex Therapeutics Inc (CLDX) recorded an outflow of $213.7M in free cash flow during fiscal year 2025. This represents a -33.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Celldex Therapeutics Inc's operating cash flow?
Celldex Therapeutics Inc (CLDX) recorded an outflow of $210.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Celldex Therapeutics Inc's total assets?
Celldex Therapeutics Inc (CLDX) had $583.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Celldex Therapeutics Inc's capital expenditures?
Celldex Therapeutics Inc (CLDX) invested $2.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Celldex Therapeutics Inc spend on research and development?
Celldex Therapeutics Inc (CLDX) invested $245.1M in research and development during fiscal year 2025.
What is Celldex Therapeutics Inc's current ratio?
Celldex Therapeutics Inc (CLDX) had a current ratio of 10.49 as of fiscal year 2025, which is generally considered healthy.
What is Celldex Therapeutics Inc's debt-to-equity ratio?
Celldex Therapeutics Inc (CLDX) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Celldex Therapeutics Inc's return on assets (ROA)?
Celldex Therapeutics Inc (CLDX) had a return on assets of -44.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Celldex Therapeutics Inc's P/E ratio?
Celldex Therapeutics Inc (CLDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.1B as of Sep 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Celldex Therapeutics Inc's price-to-sales ratio?
Celldex Therapeutics Inc (CLDX) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $1.5M revenue, FY2025). The market capitalization is $3.1B as of Sep 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Celldex Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Celldex Therapeutics Inc (CLDX) held $518.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $210.9M over that year. Dividing the one by the other, the reported balance equals about 29 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Celldex Therapeutics Inc's Altman Z-Score?
Celldex Therapeutics Inc (CLDX) has an Altman Z-Score of 28.51, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Celldex Therapeutics Inc's Piotroski F-Score?
Celldex Therapeutics Inc (CLDX) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Celldex Therapeutics Inc's earnings high quality?
Celldex Therapeutics Inc (CLDX) reported a net loss of $258.8M while operations used $210.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Celldex Therapeutics Inc?
Celldex Therapeutics Inc (CLDX) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.